KRUPA PATEL: Open Payments
NPI 1205295060 · SCOTTSDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,214 in 53 payments from 16 companies in 2025. Trend: 2023 $903 · 2024 $1,440 · 2025 $1,214
Food & beverage: $1,214
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 14 | $317 |
| PFIZER INC. | 7 | $130 |
| E.R. Squibb & Sons, L.L.C. | 2 | $117 |
| BridgeBio Pharma, Inc. | 4 | $98 |
| Esperion Therapeutics, Inc. | 2 | $81 |
| Novo Nordisk Inc | 3 | $74 |
| Alnylam Pharmaceuticals Inc. | 4 | $71 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 6 | $68 |
| Actelion Pharmaceuticals US, Inc. | 2 | $60 |
| Boston Scientific Corporation | 1 | $41 |
Products named: LEQVIO, CAMZYOS, Attruby, NEXLETOL, VYNDAQEL, Wegovy, AMVUTTRA, LifeVest.
Industry payments across AZ — which companies pay providers there.
